|Articles|January 1, 2013
A new treatment paradigm for POAG?
Managing neuroinflammation could represent a promising new therapeutic approach in glaucoma
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
2
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
3
FLORetina 2025: Rethinking Terson syndrome through multimodal imaging
4
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
5









































